Details for New Drug Application (NDA): 205237
✉ Email this page to a colleague
The generic ingredient in LACOSAMIDE is lacosamide. There are twenty-two drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the lacosamide profile page.
Summary for 205237
Tradename: | LACOSAMIDE |
Applicant: | Sciegen Pharms Inc |
Ingredient: | lacosamide |
Patents: | 0 |
Formulation / Manufacturing: | see details |
Pharmacology for NDA: 205237
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 205237
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LACOSAMIDE | lacosamide | TABLET;ORAL | 205237 | ANDA | ScieGen Pharmaceuticals Inc | 50228-192 | 50228-192-10 | 1000 TABLET, FILM COATED in 1 BOTTLE (50228-192-10) |
LACOSAMIDE | lacosamide | TABLET;ORAL | 205237 | ANDA | ScieGen Pharmaceuticals Inc | 50228-192 | 50228-192-30 | 30 TABLET, FILM COATED in 1 BOTTLE (50228-192-30) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
Approval Date: | Mar 17, 2022 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
Approval Date: | Mar 17, 2022 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
Approval Date: | Mar 17, 2022 | TE: | AB | RLD: | No |
Complete Access Available with Subscription